CN Patent

CN120093765A — 瑞司美替罗联合二甲双胍或其药学上可接受的盐在制备药物中的应用

Assigned to Institute of Medicinal Plant Development of CAMS and PUMC · Expires 2025-06-06 · 1y expired

What this patent protects

本发明属于生物医药研究领域，具体涉及瑞司美替罗联合二甲双胍或其药学上可接受的盐在制备药物中的应用。本发明通过瑞司美替罗（简写为Res）联合二甲双胍或其药学上可接受的盐联合用药，在降低瑞司美替罗的用药剂量的基础上显著提升了代谢功能障碍相关性脂肪性肝病所导致的炎症方面的疗效。并且证明了两者加合后对炎症的抑制作用都显著优于两者单独用药，产生了协同增效的作用。

USPTO Abstract

本发明属于生物医药研究领域，具体涉及瑞司美替罗联合二甲双胍或其药学上可接受的盐在制备药物中的应用。本发明通过瑞司美替罗（简写为Res）联合二甲双胍或其药学上可接受的盐联合用药，在降低瑞司美替罗的用药剂量的基础上显著提升了代谢功能障碍相关性脂肪性肝病所导致的炎症方面的疗效。并且证明了两者加合后对炎症的抑制作用都显著优于两者单独用药，产生了协同增效的作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN120093765A
Jurisdiction
CN
Classification
—
Expires
2025-06-06
Drug substance claim
No
Drug product claim
No
Assignee
Institute of Medicinal Plant Development of CAMS and PUMC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.